Condition

Muscle-invasive Bladder Cancer clinical trials and research

• 11Clinical trials
• 19NIH research projects
• 15Countries

Newest Muscle-invasive Bladder Cancer clinical trials

All recruiting trials (11)

• FDG PET/CT for Muscle-Invasive Bladder Cancer: Baseline Staging and Chemotherapy Response

  This study tests how well 18F-FDG PET/CT can stage muscle-invasive bladder cancer and predict how patients respond to neoadjuvant chemotherapy.

  Recruiting University Hospital of Ferrara · Ferrara · NCT07750470

• Enfortumab vedotin plus pembrolizumab to help people with muscle-invasive bladder cancer keep their bladder

  This trial tests whether giving enfortumab vedotin together with pembrolizumab can let people with muscle-invasive bladder cancer avoid bladder removal.

  Recruiting at 68 sites Phase 2 Astellas Pharma Inc · Little Rock, Arkansas and 67 other locations · NCT07475806

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Pre-surgery chemotherapy and MRI accuracy for staging muscle-invasive bladder cancer

  This project will see if giving chemotherapy before surgery changes how accurately MRI can stage muscle-invasive bladder cancer in people scheduled for cystectomy.

  Recruiting Assiut University · Asyut, Asyut Governorate and 1 other locations · NCT07202819

• Combining rutin with immunotherapy and chemotherapy for bladder cancer treatment

  This study is testing if adding rutin to standard bladder cancer treatments can help patients whose cancer hasn't responded to chemotherapy feel better and improve their outcomes.

  Recruiting Phase 1 First Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT06916494

• Tetra-modality bladder-preservation approach in muscle-invasive bladder cancer

  This trial tests whether adding the immunotherapy drug avelumab to tumor removal, chemotherapy, and radiation can help people with muscle-invasive bladder cancer keep their bladder.

  Recruiting Phase 2 American University of Beirut Medical Center · Beirut, Beirut · NCT06686381

• Combination therapy for high-risk muscle-invasive bladder cancer

  This study is testing if a combination of two cancer drugs can help people with high-risk bladder cancer stay cancer-free after surgery.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06682728

• Erdafitinib with or without Cetrelimab for muscle-invasive bladder cancer

  This study is testing if a new drug called erdafitinib, alone or with another drug called cetrelimab, can help people with muscle-invasive bladder cancer who can’t take certain chemotherapy drugs before their surgery.

  Recruiting at 19 sites Phase 2 Spanish Oncology Genito-Urinary Group · Clermont-Ferrand and 22 other locations · NCT06511648

• Predicting chemotherapy response in bladder cancer patients

  This study is trying to see if looking at the genes and molecules in bladder cancer patients can help figure out who will respond well to chemotherapy and who might need different treatments.

  Recruiting Yonsei University · Seoul · NCT06373055

• Comparing mpMRI and TURBT for diagnosing muscle-invasive bladder cancer

  This study is testing whether a special type of MRI can accurately diagnose muscle-invasive bladder cancer compared to a common surgical procedure in patients who might have this type of cancer.

  Recruiting University of California, Irvine · Orange, California · NCT06335667

• Using advanced MRI to improve diagnosis of muscle-invasive bladder cancer

  This study is testing whether a new MRI method can improve the diagnosis of muscle-invasive bladder cancer compared to the standard procedure to see which one is better for patients.

  Recruiting at 15 sites Radboud University Medical Center · 's-Hertogenbosch and 18 other locations · NCT05779631

NIH-funded research (19)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Nrf2 in T cells and how it could boost immune power against bladder cancer

  A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.

  NIH research University of Kansas Medical Center · Kansas City, United States · NIH-11441846

• Repurposing spironolactone to treat bladder cancer inside the bladder

  Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11420769

• Body fats and immune signals shaping bladder cancer outlook

  This study will look at how body composition and immune/inflammatory states at diagnosis relate to the outlook for people with non-muscle-invasive bladder cancer.

  NIH research Kaiser Foundation Research Institute · Oakland, UNITED STATES · NIH-11337623

• Novel combination immunotherapy for non–muscle-invasive bladder cancer

  Researchers are testing a new combination approach using a special anti-CD40 antibody with existing bladder cancer therapies to help patients whose NMIBC did not respond to standard BCG treatment.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11335850

• Why some bladder cancers don't respond to BCG treatment

  This project will use detailed tissue and genetic tests to look for what makes some non-muscle invasive bladder cancers resist BCG so better treatments can be found for people who don't respond.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11322536

• Salt-based nanomedicine to treat bladder cancer that doesn’t respond to standard BCG therapy

  A patient-focused overview of a new salt-based nanoparticle therapy designed to target non-muscle invasive bladder cancer that is resistant to BCG treatment.

  NIH research Athna Biotech, INC. · Athens, UNITED STATES · NIH-11314266

• HLA‑E/NKG2A immune 'brake' in early bladder cancer

  The team is exploring whether targeting an immune 'brake' called HLA‑E/NKG2A can help people with non‑muscle‑invasive (early) bladder cancer who receive BCG therapy.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11285326

• Targeted Internal Radiation and Immune Therapy for Non-Muscle-Invasive Bladder Cancer

  Aims to help people with early bladder cancer that doesn’t respond to current therapy by using a novel intravesical treatment that combines targeted radiation, immune checkpoint inhibitors, and oncolytic virus to trigger a strong anti-cancer response.

  NIH research Vanderbilt University · Nashville, UNITED STATES · NIH-11280102

• Improving bladder-sparing treatment for muscle-invasive bladder cancer by targeting DNA repair changes

  This work looks at whether bladder cancers with specific DNA-repair gene changes make bladder-preserving chemo-and-radiation more effective so more patients can avoid bladder removal.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11162292

• Blood test to monitor bladder-preserving treatment for muscle-invasive bladder cancer

  This project will use blood tests to see if cancer cells or tumor DNA in the blood can help guide and monitor bladder-preserving treatment for people with muscle-invasive bladder cancer.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11144446

• Urine testing as a less invasive follow-up for early bladder cancer

  This project compares urine-based tests with routine cystoscopy for people being monitored after early-stage (non-muscle invasive) bladder cancer.

  NIH research Veterans Education/res/assn/north/ne · White River Junction, United States · NIH-11142415

• Investigating BCG resistance in bladder cancer to find new treatment options

  This study is looking at why some people with non-muscle invasive bladder cancer don’t respond to the usual treatment with BCG, by examining their tumor samples to find clues that could help improve future treatments.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11108450

• How body composition and inflammation affect outcomes in bladder cancer

  This study is looking at how things like weight and muscle loss affect the health and treatment of people with early-stage bladder cancer, hoping to find ways to better predict outcomes and tailor treatments for patients.

  NIH research Kaiser Foundation Research Institute · Oakland, UNITED STATES · NIH-11096087

• Investigating immune responses in non-muscle-invasive bladder cancer

  This study is looking at how your immune system reacts to the BCG treatment for non-muscle-invasive bladder cancer, with the hope of finding ways to make the treatment work better and reduce the chances of the cancer coming back.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11020945

• Improving bladder cancer treatment by targeting DNA repair deficiencies

  This study is looking at how certain gene changes in people with muscle-invasive bladder cancer might help doctors decide the best treatment options, like whether to remove the bladder or use a combination of chemotherapy and radiation, to improve outcomes for patients.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-10918108

• Understanding non-muscle invasive bladder cancer and its treatment options

  This study is looking to help people with non-muscle invasive bladder cancer by finding better ways to predict if their cancer might come back and to see who might not do well with the usual treatment, so they can get more personalized care based on their unique tumor traits.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-10907672

• Using urine tests instead of invasive procedures for bladder cancer follow-up

  This study is looking at whether urine tests can replace the uncomfortable cystoscopy procedures for people with non-muscle invasive bladder cancer, making it easier to check for cancer recurrence while keeping patients safe and healthy.

  NIH research Veterans Education/res/assn/north/ne · White River Junction, United States · NIH-10893922

• Monitoring blood for bladder cancer treatment effectiveness

  This study is looking at a new way to treat muscle-invasive bladder cancer using a mix of chemotherapy and radiation, while also developing blood tests to help doctors see how well the treatment is working and if the cancer comes back, so they can create more personalized care for patients.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-10892275

• Understanding how bladder cancer resists treatment with BCG therapy

  This study is looking into why some people with non-muscle invasive bladder cancer don’t get better with the usual BCG treatment, and it aims to find new ways to help those patients by understanding how their immune system might be resisting the therapy.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-10881778

Related topics

Quick answers

How many Muscle-invasive Bladder Cancer clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 15 countries. The most sites are in United States (4 trials), Italy (3 trials), South Korea (2 trials), China (2 trials), France (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →